4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
A phase 2 trial of Resminostat and Sorafenib in Hepatocellular carcinoma, run by 4SC AG, completed.
Overview
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT00943449 by 4SC AG, with 57 participants recorded, started 2009-07 and reaching its primary completion in 2012-06. Interventions recorded: 4SC-201, Sorafenib. Conditions recorded: Hepatocellular Carcinoma.
Linked to the drug Resminostat because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialResminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
Shares 4SC, Resminostat and the tag pipeline.
- TrialResminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Shares 4SC, Resminostat and the tag pipeline.
- TrialEvaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Shares Sorafenib and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialThermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialNWRD06 DNA Plasmid for HCC After Curative Resection.
Shares Hepatocellular carcinoma and the tag pipeline.